CD52 and cancer: Similar with CD3D and CD52, CD79A and CD37 can not only help us monitor specific T–B interactions, which is one of the major parts of the anti-cancer immune response, but can also provide us a new biomarker to evaluate the alteration of cancer microenvironment during tumorigenesis.